Search Results - "Druker, Brian J"

Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia by Hochhaus, Andreas, Larson, Richard A, Guilhot, François, Radich, Jerald P, Branford, Susan, Hughes, Timothy P, Baccarani, Michele, Deininger, Michael W, Cervantes, Francisco, Fujihara, Satoko, Ortmann, Christine-Elke, Menssen, Hans D, Kantarjian, Hagop, O’Brien, Stephen G, Druker, Brian J

“…After nearly 11 years of follow-up, long-term administration of imatinib was shown to be associated with prolonged control of chronic myeloid leukemia and no…”
Get full text

Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-Mediated Targeted Protein Degradation by Burslem, George M, Schultz, Anna Reister, Bondeson, Daniel P, Eide, Christopher A, Savage Stevens, Samantha L, Druker, Brian J, Crews, Craig M

“…Although the use of ATP-competitive tyrosine kinase inhibitors of oncoprotein BCR-ABL1 has enabled durable responses in patients with chronic myeloid leukemia…”
Get full text

FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia by Traer, Elie, Martinez, Jacqueline, Javidi-Sharifi, Nathalie, Agarwal, Anupriya, Dunlap, Jennifer, English, Isabel, Kovacsovics, Tibor, Tyner, Jeffrey W, Wong, Melissa, Druker, Brian J

“…Potent FLT3 inhibitors, such as quizartinib (AC220), have shown promise in treating acute myeloid leukemia (AML) containing FLT3 internal tandem duplication…”
Get full text

The development of imatinib as a therapeutic agent for chronic myeloid leukemia by Deininger, Michael, Buchdunger, Elisabeth, Druker, Brian J.

“…Imatinib has revolutionized drug therapy of chronic myeloid leukemia (CML). Preclinical studies were promising but the results of clinical trials by far…”
Get full text

Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms by Zhang, Haijiao, Savage, Samantha, Schultz, Anna Reister, Bottomly, Daniel, White, Libbey, Segerdell, Erik, Wilmot, Beth, McWeeney, Shannon K., Eide, Christopher A., Nechiporuk, Tamilla, Carlos, Amy, Henson, Rachel, Lin, Chenwei, Searles, Robert, Ho, Hoang, Lam, Yee Ling, Sweat, Richard, Follit, Courtney, Jain, Vinay, Lind, Evan, Borthakur, Gautam, Garcia-Manero, Guillermo, Ravandi, Farhad, Kantarjian, Hagop M., Cortes, Jorge, Collins, Robert, Buelow, Daelynn R., Baker, Sharyn D., Druker, Brian J., Tyner, Jeffrey W.

“…FLT3 mutations are prevalent in AML patients and confer poor prognosis. Crenolanib, a potent type I pan-FLT3 inhibitor, is effective against both internal…”
Get full text

Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias by Cortes, Jorge E, Kantarjian, Hagop, Shah, Neil P, Bixby, Dale, Mauro, Michael J, Flinn, Ian, O'Hare, Thomas, Hu, Simin, Narasimhan, Narayana I, Rivera, Victor M, Clackson, Tim, Turner, Christopher D, Haluska, Frank G, Druker, Brian J, Deininger, Michael W.N, Talpaz, Moshe

“…Ponatinib was developed to overcome resistance to the tyrosine kinase inhibitors used to treat leukemias that are positive for the Philadelphia chromosome. In…”
Get full text

Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid Leukemia by Carey, Alyssa, Edwards, David K., Eide, Christopher A., Newell, Laura, Traer, Elie, Medeiros, Bruno C., Pollyea, Daniel A., Deininger, Michael W., Collins, Robert H., Tyner, Jeffrey W., Druker, Brian J., Bagby, Grover C., McWeeney, Shannon K., Agarwal, Anupriya

“…Secreted proteins in the bone marrow microenvironment play critical roles in acute myeloid leukemia (AML). Through an ex vivo functional screen of 94…”
Get full text

A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer by Drilon, Alexander, Somwar, Romel, Wagner, Jacob P, Vellore, Nadeem A, Eide, Christopher A, Zabriskie, Matthew S, Arcila, Maria E, Hechtman, Jaclyn F, Wang, Lu, Smith, Roger S, Kris, Mark G, Riely, Gregory J, Druker, Brian J, O'Hare, Thomas, Ladanyi, Marc, Davare, Monika A

“…Rearranged ROS1 is a crizotinib-sensitive oncogenic driver in lung cancer. The development of acquired resistance, however, poses a serious clinical challenge…”
Get full text

Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia by Branford, Susan, Kim, Dennis Dong Hwan, Apperley, Jane F., Eide, Christopher A., Mustjoki, Satu, Ong, S. Tiong, Nteliopoulos, Georgios, Ernst, Thomas, Chuah, Charles, Gambacorti-Passerini, Carlo, Mauro, Michael J., Druker, Brian J., Kim, Dong-Wook, Mahon, Francois-Xavier, Cortes, Jorge, Radich, Jerry P., Hochhaus, Andreas, Hughes, Timothy P.

“…Outcomes for patients with chronic myeloid leukemia (CML) have substantially improved due to advances in drug development and rational treatment intervention…”
Get full text

Thrombotic microangiopathy as a cause of cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib by Latifi, Yllka, Moccetti, Federico, Wu, Melinda, Xie, Aris, Packwood, William, Qi, Yue, Ozawa, Koya, Shentu, Weihui, Brown, Eran, Shirai, Toshiaki, McCarty, Owen J., Ruggeri, Zaverio, Moslehi, Javid, Chen, Junmei, Druker, Brian J., López, Jose A., Lindner, Jonathan R.

“…The third-generation tyrosine kinase inhibitor (TKI) ponatinib has been associated with high rates of acute ischemic events. The pathophysiology responsible…”
Get full text

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS) by Hughes, Timothy P., Hochhaus, Andreas, Branford, Susan, Müller, Martin C., Kaeda, Jaspal S., Foroni, Letizia, Druker, Brian J., Guilhot, François, Larson, Richard A., O'Brien, Stephen G., Rudoltz, Marc S., Mone, Manisha, Wehrle, Elisabeth, Modur, Vijay, Goldman, John M., Radich, Jerald P.

“…This study examines the prognostic significance of early molecular response using an expanded dataset in chronic myeloid leukemia patients enrolled in the…”
Get full text

Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors by Davare, Monika A., Vellore, Nadeem A., Wagner, Jacob P., Eide, Christopher A., Goodman, James R., Drilon, Alexander, Deininger, Michael W., O’Hare, Thomas, Druker, Brian J.

“…Oncogenic ROS1 fusion proteins are molecular drivers in multiple malignancies, including a subset of non-small cell lung cancer (NSCLC). The phylogenetic…”
Get full text

Crosstalk between ROR1 and the Pre-B Cell Receptor Promotes Survival of t(1;19) Acute Lymphoblastic Leukemia by Bicocca, Vincent T., Chang, Bill H., Masouleh, Behzad Kharabi, Muschen, Markus, Loriaux, Marc M., Druker, Brian J., Tyner, Jeffrey W.

“…We report that t(1;19) ALL cells universally exhibit expression of and dependence on the cell surface receptor ROR1. We further identify t(1;19) ALL cell…”
Get full text

Understanding Drug Sensitivity and Tackling Resistance in Cancer by Tyner, Jeffrey W, Haderk, Franziska, Kumaraswamy, Anbarasu, Baughn, Linda B, Van Ness, Brian, Liu, Song, Marathe, Himangi, Alumkal, Joshi J, Bivona, Trever G, Chan, Keith Syson, Druker, Brian J, Hutson, Alan D, Nelson, Peter S, Sawyers, Charles L, Willey, Christopher D

“…Decades of research into the molecular mechanisms of cancer and the development of novel therapeutics have yielded a number of remarkable successes. However,…”
Get full text

Nilotinib and MEK Inhibitors Induce Synthetic Lethality through Paradoxical Activation of RAF in Drug-Resistant Chronic Myeloid Leukemia by Packer, Leisl M., Rana, Sareena, Hayward, Robert, O'Hare, Thomas, Eide, Christopher A., Rebocho, Ana, Heidorn, Sonja, Zabriskie, Matthew S., Niculescu-Duvaz, Ion, Druker, Brian J., Springer, Caroline, Marais, Richard

“…We show that imatinib, nilotinib, and dasatinib possess weak off-target activity against RAF and, therefore, drive paradoxical activation of BRAF and CRAF in a…”
Get full text

Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia by Druker, Brian J, Guilhot, François, O'Brien, Stephen G, Gathmann, Insa, Kantarjian, Hagop, Gattermann, Norbert, Deininger, Michael W.N, Silver, Richard T, Goldman, John M, Stone, Richard M, Cervantes, Francisco, Hochhaus, Andreas, Powell, Bayard L, Gabrilove, Janice L, Rousselot, Philippe, Reiffers, Josy, Cornelissen, Jan J, Hughes, Timothy, Agis, Hermine, Fischer, Thomas, Verhoef, Gregor, Shepherd, John, Saglio, Giuseppe, Gratwohl, Alois, Nielsen, Johan L, Radich, Jerald P, Simonsson, Bengt, Taylor, Kerry, Baccarani, Michele, So, Charlene, Letvak, Laurie, Larson, Richard A

“…The constitutively active BCR-ABL tyrosine kinase is the cause of chronic myeloid leukemia. Imatinib is the first small synthetic molecular inhibitor of the…”
Get full text

Understanding cancer from the stem cells up by Eide, Christopher A, Druker, Brian J

“…A new study that uses an integrated single-cell transcriptomics approach to characterize cancer stem cell populations during treatment with molecularly…”
Get full text

Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations by Müller, Martin C., Cortes, Jorge E., Kim, Dong-Wook, Druker, Brian J., Erben, Philipp, Pasquini, Ricardo, Branford, Susan, Hughes, Timothy P., Radich, Jerald P., Ploughman, Lynn, Mukhopadhyay, Jaydip, Hochhaus, Andreas

“…Dasatinib is a BCR-ABL inhibitor with 325-fold higher potency than imatinib against unmutated BCR-ABL in vitro. Imatinib failure is commonly caused by BCR-ABL…”
Get full text

Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug Resistance by Javidi-Sharifi, Nathalie, Traer, Elie, Martinez, Jacqueline, Gupta, Anu, Taguchi, Takehiro, Dunlap, Jennifer, Heinrich, Michael C, Corless, Christopher L, Rubin, Brian P, Druker, Brian J, Tyner, Jeffrey W

“…Kinase inhibitors such as imatinib have dramatically improved outcomes for patients with gastrointestinal stromal tumor (GIST), but many patients develop…”
Get full text

A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia by Ma, Leyuan, Shan, Yi, Bai, Robert, Xue, Liting, Eide, Christopher A, Ou, Jianhong, Zhu, Lihua J, Hutchinson, Lloyd, Cerny, Jan, Khoury, Hanna Jean, Sheng, Zhi, Druker, Brian J, Li, Shaoguang, Green, Michael R

“…Resistance to the BCR-ABL inhibitor imatinib mesylate (IM) poses a major problem for the treatment of chronic myeloid leukemia (CML). IM resistance often…”
Get more information